ConquerAb

Executive Summary

ConquerAb Inc. is a pre-clinical biotechnology company developing rapid, disposable diagnostic devices for detecting antibody responses against protein-based biotherapeutics. Founded in 2021 and based in Cambridge, USA, the company aims to standardize immunogenicity testing, enabling precision medicine and data integration for AI applications. Its point-of-care and at-home devices require only a drop of blood and deliver results in under 15 minutes, addressing a critical need for consistent, real-time monitoring of biologic therapies. With immunogenicity impacting up to 30% of patients on biotherapeutics, ConquerAb's technology could reduce treatment failures, improve patient outcomes, and lower healthcare costs. The company is currently in the pre-clinical stage, focusing on device optimization and initial validation. While no funding or partnership details are available, its novel approach to a widespread problem positions it well in the growing companion diagnostics market. Success will depend on clinical validation, regulatory clearance, and commercial partnerships. The diagnostics space is competitive, but ConquerAb's focus on simplicity and speed offers a differentiated value proposition.

Upcoming Catalysts (preview)

• Q1 2027Completion of first clinical validation study60% success
• Q4 2026Establishment of strategic partnership with a top-20 pharma company40% success
• Q2 2027Submission of 510(k) premarket notification to FDA30% success